文献速递肾小球疾病

上皮细胞PDGF-C通过激活壁层上皮细胞促进新月体性肾小球肾炎和FSGS

Epithelial PDGF-C Contributes to Crescentic Glomerulonephritis and FSGS in Part via Activation of Parietal Epithelial Cells.
PubMed 文献 · J Am Soc Nephrol · 2026-10-09

研究探讨上皮细胞来源的PDGF-C在新月体性肾小球肾炎和局灶节段性肾小球硬化(FSGS)中的作用。在小鼠模型和体外实验中,PDGF-C在壁层上皮细胞(PECs)中上调并在足细胞中重新表达,促进PECs增殖和活化;遗传或药理抑制PDGF-C可改善肾小球新月体形成、硬化、炎症和肾功能。机制上FOXM1介导PECs中PDGF-C的表达。

要点

  • PDGF-C在病变肾小球PECs中上调并在足细胞中重新表达。
  • 抑制PDGF-C可减轻小鼠新月体形成、肾小球硬化和炎症。
  • FOXM1转录因子介导PECs中疾病相关PDGF-C表达。

核心结论

  • 上皮细胞PDGF-C通过部分激活壁层上皮细胞促进新月体性肾小球肾炎和FSGS进展。

研究设计与样本

  • 在小鼠和人类肾组织中分析PDGF-C及受体PDGFRα表达。
  • 在Pdgfc缺陷小鼠、PDGF-C中和抗体治疗小鼠及Pax8-cre::Pdgfcfl/fl条件性敲除小鼠中诱导肾毒血清肾炎模型。
  • 在抗Thy1.1转基因小鼠塌陷性FSGS模型中给予PDGF-C药理学抑制。
  • 辅以原代及条件永生化PECs的体外分析。

主要发现

  • PDGF-C在病变PECs中上调并在足细胞中重新表达。
  • PDGF-C促进原代及条件永生化PECs的增殖和活化。
  • 遗传或药理PDGF-C干预均显著改善肾小球新月体形成、肾小球硬化、肾脏炎症和肾功能参数。
  • FOXM1被鉴定为PECs中疾病相关PDGF-C表达的介质。

临床怎么用

  • PDGF-C通路可能成为新月体性肾小球肾炎和FSGS的潜在治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Activated parietal epithelial cells (PECs) and podocytes are key effector cells in the development of crescentic glomerulonephritis and focal segmental glomerulosclerosis (FSGS). Platelet-derived growth factor (PDGF)-C has been found to be important for tubulointerstitial fibrosis development, but its relevance for crescentic glomerulonephritis and FSGS was previously unknown. METHODS: To address this, expression analyses for both PDGF-C and its receptor PDGFRα were carried out in mouse and human kidney tissues. To further elucidate a functional role of PDGF-C, the murine nephrotoxic nephritis model of crescentic glomerulonephritis was induced in a) Pdgfc-deficient mice, b) mice treated with a neutralizing PDGF-C antibody, and c) Pax8-cre::Pdgfcfl/fl mice with conditional Pdgfc deletion in kidney epithelial cells. We also subjected the collapsing FSGS model of the anti-Thy1.1 transgenic mouse to pharmacological PDGF-C inhibition. The studies were supplemented by PEC in vitro analyses. RESULTS: Our data showed that PDGF-C was upregulated in PECs and expressed de novo in podocytes under disease conditions. It promoted the proliferation and activation of primary as well as conditionally immortalized PECs in vitro. In both the genetic and pharmacological PDGF-C intervention studies in murine crescentic glomerulonephritis and FSGS, significant improvements in glomerular crescent formation, glomerular sclerosis, renal inflammation and kidney function parameters were observed upon PDGF-C deficiency or antagonism. Mechanistically, transcription factor FOXM1 was identified as a mediator of disease-related PDGF-C expression in PECs. CONCLUSIONS: Our studies identified epithelial PDGF-C as a contributor to disease progression in crescentic glomerulonephritis and FSGS, acting in part through the activation of parietal epithelial cells.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Martin IV, Gao Y, Wong DWL, et al. Epithelial PDGF-C Contributes to Crescentic Glomerulonephritis and FSGS in Part via Activation of Parietal Epithelial Cells. J Am Soc Nephrol. 2026. PMID: 42853622. doi:10.1681/ASN.0000001274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。